All News
FDA Approves Rinvoq for Giant Cell Arteritis
Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication for upadacitinib in the U.S. for use in rheumatology, gastroenterology, and dermatology.
Read ArticleMetformin Effective in Osteoarthritis
The diabetes drug metformin provided overweight/obese patients with osteoarthritis (OA) of the knee with significantly greater pain relief than did placebo in a small randomized trial, researchers said.
Read Article2024 Management of Familial Mediterranean Fever Recommendations
A EULAR/PReS combined task force has developed recommendations for the management of Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease worldwide. These evidence-based recommendations update the 2016 recommendations developed for rheumatologists and other HCPs who care for FMF patients.
Read Article
Dr. John Cush RheumNow ( View Tweet)



Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)




Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)


Links:




